Cover Image
市場調查報告書

B型血友病:開發平台分析

Hemophilia B - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232835
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
B型血友病:開發平台分析 Hemophilia B - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 112 Pages
簡介

B型血友病是由於第IX凝血因子不足造成的遺傳性出血疾病。如果缺乏足夠的第九凝血因子,就無法凝固血液,有效地堵住出血部位。主要症狀有關節內出血,以及伴隨而來的關節痛·腫脹,紫斑,伴隨環狀切除的大量出血,消化道·尿道出血,鼻血等。主要的治療方法有補充缺箏的凝血因子等。

本報告提供全球各國治療B型血友病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

B型血友病概要

治療藥的開發

  • B型血友病開發中產品:概要
  • B型血友病開發中產品:比較分析

各企業開發中的B型血友病治療藥

大學/研究機關研究中的B型血友病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

B型血友病治療藥:開發中的產品一覽(各企業)

按B型血友病治療藥:研究中的產品一覽(大學/研究機關)

B型血友病治療藥的開發企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca Plc
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • RegenxBio Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.

B型血友病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • albutrepenonacog alfa
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ALN-AT3
  • AMT-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • CB-813d
  • B型血友病細胞療法
  • 第IX凝血因子(基因改造型)
  • 第IX凝血因子(基因改造型)
  • 第IX凝血因子FC(基因改造型), Fc 融合蛋白品質
  • 第VIIa凝血因子 (基因改造型)
  • concizumab
  • CSL-689
  • DTX-101
  • B型血友病遺傳基因療法
  • B型血友病第九凝血因子活性化用遺傳基因療法
  • B型血友病第九凝血因子活性化用遺傳基因療法
  • MOD-5014
  • MOD-9017
  • nonacog beta pegol
  • PF-06741086
  • SB-FIX
  • SPK-FIX
  • SVF-VIIa

B型血友病治療藥:開發中產品的最新趨勢

B型血友病治療藥:開發暫停的產品

B型血友病治療藥:開發中止的產品

B型血友病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9186IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia B - Overview
    • Hemophilia B - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hemophilia B - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hemophilia B - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Amarna Therapeutics BV
    • Bayer AG
    • Bioverativ Inc
    • Catalyst Biosciences Inc
    • China Biologic Products Inc
    • CSL Ltd
    • Dimension Therapeutics Inc
    • Genethon SA
    • Green Cross Corp
    • MolMed SpA
    • Novo Nordisk A/S
    • OPKO Biologics Ltd
    • Pfizer Inc
    • Pharming Group NV
    • Promethera Biosciences SA
    • RegenxBio Inc
    • rEVO Biologics Inc
    • Sangamo Therapeutics Inc
    • Shire Plc
    • Spark Therapeutics Inc
    • UniQure NV
  • Hemophilia B - Drug Profiles
    • AMT-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAX-335 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1093884 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIVV-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-2679d - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant), pegylated - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • concizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fitusiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hematological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HepaStem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LR-769 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marzeptacog alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-1113A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOD-5014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06741086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-FIX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPK-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVF-VIIa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hemophilia B - Dormant Projects
  • Hemophilia B - Discontinued Products
  • Hemophilia B - Product Development Milestones
    • Featured News & Press Releases
      • Apr 11, 2017: Key Milestone Reached in Catalyst's Subcutaneous Factor IX Program
      • Mar 31, 2017: FDA posts briefing materials prior to Advisory Committee meeting for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B
      • Mar 30, 2017: Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated), Catalyst's Lead Clinical Program
      • Mar 28, 2017: Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program
      • Mar 23, 2017: Novo Nordisk Receives CHMP Positive opinion For Refixia
      • Mar 02, 2017: Long-term safety and efficacy extension study data of Alprolix for haemophilia B published in Thrombosis and Haemostasis
      • Feb 14, 2017: Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference
      • Feb 02, 2017: Long-term safety and efficacy data of extended half-life therapy Alprolix in children with haemophilia B published in The Lancet Haematology
      • Feb 02, 2017: Alnylam Presents New Data on Fitusiran at EAHAD
      • Feb 01, 2017: Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factor IX at EAHAD Annual Congress
      • Feb 01, 2017: Sobi and Bioverativ to reveal new long-term safety and efficacy data of Alprolix at EAHAD
      • Feb 01, 2017: Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factor VIIa at EAHAD Annual Congress
      • Jan 26, 2017: Catalyst Biosciences Announces Presentation on investigational coagulation factor CB 2679d at the 2017 Congress of the European Association of Haemophilia and Allied Disorders
      • Jan 26, 2017: Catalyst Biosciences Announces Data Presentation on Marzeptacog alfa at the 2017 Congress of the European Association of Haemophilia and Allied Disorders
      • Jan 06, 2017: FDA Accepts For Review LFB's BLA For Its Recombinant Factor VII
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia B, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hemophilia B - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
  • Hemophilia B - Pipeline by Amarna Therapeutics BV, H1 2017
  • Hemophilia B - Pipeline by Bayer AG, H1 2017
  • Hemophilia B - Pipeline by Bioverativ Inc, H1 2017
  • Hemophilia B - Pipeline by Catalyst Biosciences Inc, H1 2017
  • Hemophilia B - Pipeline by China Biologic Products Inc, H1 2017
  • Hemophilia B - Pipeline by CSL Ltd, H1 2017
  • Hemophilia B - Pipeline by Dimension Therapeutics Inc, H1 2017
  • Hemophilia B - Pipeline by Genethon SA, H1 2017
  • Hemophilia B - Pipeline by Green Cross Corp, H1 2017
  • Hemophilia B - Pipeline by MolMed SpA, H1 2017
  • Hemophilia B - Pipeline by Novo Nordisk A/S, H1 2017
  • Hemophilia B - Pipeline by OPKO Biologics Ltd, H1 2017
  • Hemophilia B - Pipeline by Pfizer Inc, H1 2017
  • Hemophilia B - Pipeline by Pharming Group NV, H1 2017
  • Hemophilia B - Pipeline by Promethera Biosciences SA, H1 2017
  • Hemophilia B - Pipeline by RegenxBio Inc, H1 2017
  • Hemophilia B - Pipeline by rEVO Biologics Inc, H1 2017
  • Hemophilia B - Pipeline by Sangamo Therapeutics Inc, H1 2017
  • Hemophilia B - Pipeline by Shire Plc, H1 2017
  • Hemophilia B - Pipeline by Spark Therapeutics Inc, H1 2017
  • Hemophilia B - Pipeline by UniQure NV, H1 2017
  • Hemophilia B - Dormant Projects, H1 2017
  • Hemophilia B - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hemophilia B, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top